Do epigenetic pathways initiate late onset alzheimer disease (LOAD): Towards a new paradigm

Current Alzheimer Research

Volumn 9, Issue 5, 2012, Pages 574-588

  Bihaqi, Syed Waseem ^a   Schumacher, Axel ^b   Maloney, Bryan ^c   Lahiri, Debomoy K ^c   Zawia, Nasser H ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid hypothesis; APP; Cognitive function; LOAD

Indexed keywords

BETA SECRETASE 1; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 2; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; FRAGILE X MENTAL RETARDATION PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; METHYL CPG BINDING PROTEIN 2; MICRORNA; RNA POLYMERASE II; UNCLASSIFIED DRUG;

AGE; AGING; ALZHEIMER DISEASE; BRAIN DISEASE; BRAIN SIZE; CHROMATIN CONDENSATION; CPG ISLAND; DNA BINDING; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DNA SEQUENCE; DNA STRAND BREAKAGE; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW;

EID: 84861145950     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800617982     Document Type: Review

References (153)

1. Gimelbrant A, Hutchinson JN, Thompson BR, Chess A. Widespread monoallelic expression on human autosomes. Science 318: 1136-40 (2007).
2. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 314: 777-81 (2006).
3. Wimo A, Prince M. Word Alzheimer's Report 2010: The Global Economic Impact of Dementia. London: Alzheimer's Disease International 2010.
4. Hepburn PA, Margison GP, Tisdale MJ. Enzymatic methylation of cytosine in DNA is prevented by adjacent O6-methylguanine residues. J Biol Chem 266: 7985-7 (1991).
5. Mao P, Reddy PH. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. Biochim Biophys Acta 1812: 1359-70 (2011)
6. Golde TE. Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest 111: 11-8 (2003).
7. McGurn B, Deary IJ, Starr JM. Childhood cognitive ability and risk of late-onset Alzheimer and vascular dementia. Neurology 71: 1051-6 (2008).
8. Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 7: 208-44 (2011).
9. Wachsman JT. DNA methylation and the association between genetic and epigenetic changes: relation to carcinogenesis. Mutat Res 375: 1-8 (1997).
10. Dolinoy DC, Das R, Weidman JR, Jirtle RL. Metastable epialleles, imprinting, and the fetal origins of adult diseases. Pediatr Res 61: 30R-7R (2007).
11. Malmgren H, Steen-Bondeson ML, Gustavson KH, et al. Methylation and mutation patterns in the fragile X syndrome. Am J Med Genet 43: 268-78 (1992).
12. Ammendola R, Mesuraca M, Russo T, Cimino F. The DNAbinding efficiency of Sp1 is affected by redox changes. Eur J Biochem 225: 483-9 (1994).
13. Ghosh R, Mitchell DL. Effect of oxidative DNA damage in promoter elements on transcription factor binding. Nucleic Acids Res 27: 3213-8 (1999).
14. Dahl C, Gronbaek K, Guldberg P. Advances in DNA methylation: 5-hydroxymethylcytosine revisited. Clin Chim Acta 412: 831-6 (2011).
15. Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, Li Y, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 29: 68-72 (2011).
16. Kendler KS. Twin studies of psychiatric illness: an update. Arch Gen Psychiatry 58: 1005-14 (2001).
17. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 8: 355-67 (2007).
18. Mehler MF. Epigenetic principles and mechanisms underlying nervous system functions in health and disease. Prog Neurobiol 86: 305-41 (2008).
19. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 321: 209-13 (1986).
20. Bird A. The essentials of DNA methylation. Cell 70: 5-8 (1992).
21. Liu K, Wang YF, Cantemir C, Muller MT. Endogenous assays of DNA methyltransferases: Evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo. Mol Cell Biol 23: 2709-19 (2003).
22. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-69 (2006).
23. Feng Q, Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev 15: 827-32 (2001).
24. Holmes C, Lovestone S. The clinical phenotype of familial and sporadic late onset Alzheimer's disease. Int J Geriatr Psychiatry 17: 146-9 (2002).
25. Kalinich JF, Catravas GN, Snyder SL. The effect of gamma radiation on DNA methylation. Radiat Res 117: 185-97 (1989).
26. Feng Q, Zhang Y. The NuRD complex: linking histone modification to nucleosome remodeling. Curr Top Microbiol Immunol 274: 269-90 (2003).
27. Grant WB. Dietary links to Alzheimer's disease: 1999 update. J Alzheimers Dis 1: 197-201 (1999).
28. Brower-Toland B, Wacker DA, Fulbright RM, Lis JT, Kraus WL, Wang MD. Specific contributions of histone tails and their acetylation to the mechanical stability of nucleosomes. J Mol Biol 346: 135-46 (2005).
29. Kuo MH, vom Baur E, Struhl K, Allis CD. Gcn4 activator targets Gcn5 histone acetyltransferase to specific promoters independently of transcription. Mol Cell 6: 1309-20 (2000).
30. Kurdistani SK, Grunstein M. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 4: 276-84 (2003).
31. Sims RJ, 3rd, Nishioka K, Reinberg D. Histone lysine methylation: a signature for chromatin function. Trends Genet 19: 629-39 (2003).
32. Isalan M, Lemerle C, Michalodimitrakis K, Horn C, Beltrao P, Raineri E, et al. Evolvability and hierarchy in rewired bacterial gene networks. Nature 452: 840-5 (2008).
33. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23: 4051-60 (2004).
34. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10: 1957-66 (2004).
35. Kim VN, Nam JW. Genomics of microRNA. Trends Genet 22: 165-73 (2006).
36. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 21: 4663-70 (2002).
37. Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature 435: 745-6 (2005).
38. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 115: 787-98 (2003).
39. Rajewsky N. microRNA target predictions in animals. Nature genetics 38 Suppl: S8-13 (2006).
40. Maison C, Bailly D, Peters AH, Quivy JP, Roche D, Taddei A, et al. Higher-order structure in pericentric heterochromatin involves a distinct pattern of histone modification and an RNA component. Nature genetics 30: 329-34 (2002).
41. Bao N, Lye KW, Barton MK. MicroRNA binding sites in Arabidopsis class III HD-ZIP mRNAs are required for methylation of the template chromosome. Dev Cell 7: 653-62 (2004).
42. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol 68: 1-11 (2008).
43. Akbarian S. The neurobiology of Rett syndrome. Neuroscientist 9: 57-63 (2003).
44. Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet 1: 397-400 (1992).
45. Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. American journal of human genetics 82: 696-711 (2008).
46. de Vries BB, Jansen CC, Duits AA, Verheij C, Willemsen R, van Hemel JO, et al. Variable FMR1 gene methylation of large expansions leads to variable phenotype in three males from one fragile X family. Journal of medical genetics 33: 1007-10 (1996).
47. Petronis A. The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. Biol Psychiatry 55: 965-70 (2004).
48. Schumacher A, Petronis A. Epigenetics of complex diseases: from general theory to laboratory experiments. Curr Top Microbiol Immunol 310: 81-115 (2006).
49. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 14: 992-1003 (2009).
50. McLachlan DR, Bergeron C, Smith JE, Boomer D, Rifat SL. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology 46: 401-5 (1996).
51. Dunckley T, Beach TG, Ramsey KE, Grover A, Mastroeni D, Walker DG, et al. Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging 27: 1359-71 (2006).
52. Kaminsky Z, Wang SC, Petronis A. Complex disease, gender and epigenetics. Ann Med 38: 530-44 (2006).
53. Seeman MV. Psychopathology in women and men: focus on female hormones. Am J Psychiatry 154: 1641-7 (1997).
54. Bassett SS, Avramopoulos D, Perry RT, Wiener H, Watson B Jr, Go RC, et al. Further evidence of a maternal parent-of-origin effect on chromosome 10 in late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 141B: 537-40 (2006).
55. Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell 110: 55-67 (2002).
56. Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 10: 94-100 (2009).
57. Kim HS, Kim EM, Kim NJ, Chang KA, Choi Y, Ahn KW, et al. Inhibition of histone deacetylation enhances the neurotoxicity induced by the C-terminal fragments of amyloid precursor protein. J Neurosci Res 75: 117-24 (2004).
58. Stante M, Minopoli G, Passaro F, Raia M, Vecchio LD, Russo T. Fe65 is required for Tip60-directed histone H4 acetylation at DNA strand breaks. Proc Natl Acad Sci USA 106: 5093-8 (2009).
59. Myung NH, Zhu X, Kruman, II, Castellani RJ, Petersen RB, Siedlak SL, et al. Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age (Dordr) 30: 209-15 (2008).
60. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459: 55-60 (2009).
61. Yarbrough DE, Barrett-Connor E, Kritz-Silverstein D, Wingard DL. Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study. Diabetes Care 21: 1652-8 (1998).
62. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 9: 2395-402 (2000).
63. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 28: 3-9 (2008).
64. Feil R. Environmental and nutritional effects on the epigenetic regulation of genes. Mutat Res 600: 46-57 (2006).
65. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. Sadenosylmethionine/ homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 28: 195-204 (2005).
66. Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One 4: e6617 (2009).
67. Martin GM. Epigenetic drift in aging identical twins. Proc Natl Acad Sci USA 102: 10413-4 (2005).
68. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, Heine-Suñer D, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 102: 10604-9 (2005).
69. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One 3: e2698 (2008).
70. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120: 545-55 (2005).
71. Flanagan JM, Popendikyte V, Pozdniakovaite N, Sobolev M, Assadzadeh A, Schumacher A, et al. Intra- and interindividual epigenetic variation in human germ cells. Am J Human Genetics 79: 67-84 (2006).
72. Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol 68: 880-91 (2009).
73. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. Nat Neurosci 7: 847-54 (2004).
74. Zawia NH, Basha MR. Environmental risk factors and the developmental basis for Alzheimer's disease. Rev Neurosci 16: 325-37 (2005).
75. Bjornsson HT, Sigurdsson MI, Fallin MD, Irizarry RA, Aspelund T, Cui H, et al. Intra-individual change over time in DNA methylation with familial clustering. JAMA 299: 2877-83 (2008).
76. Slack A, Cervoni N, Pinard M, Szyf M. Feedback regulation of DNA methyltransferase gene expression by methylation. Eur J Biochem 264: 191-9 (1999).
77. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26: 137-46 (2003).
78. Dwyer BE, Takeda A, Zhu X, Perry G, Smith MA. Ferric cycle activity and Alzheimer disease. Curr Neurovasc Res 2: 261-7 (2005).
79. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 80: 114-22 (2004).
80. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. The New England journal of medicine 346: 476-83 (2002).
81. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 53: 1096-8 (1990).
82. Morrison LD, Smith DD, Kish SJ. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem 67: 1328-31 (1996).
83. Vafai SB, Stock JB. Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's Disease. FEBS Lett 518: 1-4 (2002).
84. Obeid R, Kasoha M, Knapp JP, Kostopoulos P, Becker G, Fassbender K, et al. Folate and methylation status in relation to phosphorylated tau protein(181P) and beta-amyloid(1-42) in cerebrospinal fluid. Clin Chem 53: 1129-36 (2007).
85. Guidi I, Galimberti D, Venturelli E, Lovati C, Del Bo R, Fenoglio C, et al. Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients. Neurobiol Aging 26: 789-94 (2005).
86. Lautenschlager NT, Cupples LA, Rao VS, Auerbach SA, Becker R, Burke J, et al. Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology 46: 641-50 (1996).
87. Zhang YD, Ke XY, Shen W, Liu Y. Relationship of homocysteine and gene polymorphisms of its related metabolic enzymes with Alzheimer's disease. Chin Med Sci J 20: 247-51 (2005).
88. Snowdon DA, Tully CL, Smith CD, Riley KP, Markesbery WR. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am J Clin Nutr 71: 993-8 (2000).
89. Kruman, II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22: 1752-62 (2002).
90. Coppede F. One-carbon metabolism and Alzheimer's disease: focus on epigenetics. Curr Genomics 11: 246-60 (2010).
91. Pogribny IP, Ross SA, Wise C, Pogribna M, Jones EA, Tryndyak VP, et al. Irreversible global DNA hypomethylation as a key step in hepatocarcinogenesis induced by dietary methyl deficiency. Mutat Res 593: 80-7 (2006).
92. Chan A, Shea TB. Supplementation with apple juice attenuates presenilin-1 overexpression during dietary and genetically-induced oxidative stress. J Alzheimers Dis 10: 353-8 (2006).
93. Rogers EJ, Milhalik S, Orthiz D, Shea TB. Apple juice prevents oxidative stress and impaired cognitive performance caused by genetic and dietary deficiencies in mice. J Nutr Health Aging 8: 92-7 (2004).
94. Burdge GC, Slater-Jefferies J, Torrens C, Phillips ES, Hanson MA, Lillycrop KA. Dietary protein restriction of pregnant rats in the F0 generation induces altered methylation of hepatic gene promoters in the adult male offspring in the F1 and F2 generations. Br J Nutr 97: 435-9 (2007).
95. Kirkwood TB. DNA, mutations and aging. Mutat Res: 7-13 (1988).
96. Guo JU, Su Y, Zhong C, Ming GL, Song H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle 10: 2662-8 (2011).
97. Cheutin T, McNairn AJ, Jenuwein T, Gilbert DM, Singh PB, Misteli T. Maintenance of stable heterochromatin domains by dynamic HP1 binding. Science 299: 721-5 (2003).
98. Migliore L, Coppede F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 667: 82-97 (2009).
99. Martyn CN, Coggon DN, Inskip H, Lacey RF, Young WF. Aluminum concentrations in drinking water and risk of Alzheimer's disease. Epidemiology 8: 281-6 (1997).
100. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 274: 23223-8 (1999).
101. Mutter J, Naumann J, Sadaghiani C, Schneider R, Walach H. Alzheimer disease: mercury as pathogenetic factor and apolipoprotein E as a moderator. Neuro Endocrinol Lett 25: 331-9 (2004).
102. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet 2: 577-80 (1989).
103. Barker DJ. Fetal origins of cardiovascular disease. Ann Med 31 1: 3-6 (1999).
104. Winneke G, Kramer U, Brockhaus A, Ewers U, Kujanek G, Lechner H, et al. Neuropsychological studies in children with elevated tooth-lead concentrations. II. Extended study. Int Arch Occup Environ Health 51: 231-52 (1983).
105. Barker DJ, Eriksson JG, Forsen T, Osmond C. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol 31: 1235-9 (2002).
106. Barker DJ. The developmental origins of adult disease. J Am Coll Nutr 23: 588S-95S (2004).
107. Bilbo SD, Biedenkapp JC, Der-Avakian A, Watkins LR, Rudy JW, Maier SF. Neonatal infection-induced memory impairment after lipopolysaccharide in adulthood is prevented via caspase-1 inhibition. J Neurosci 25: 8000-9 (2005).
108. Boksa P, El-Khodor BF. Birth insult interacts with stress at adulthood to alter dopaminergic function in animal models: possible implications for schizophrenia and other disorders. Neurosci Biobehav Rev 27: 91-101 (2003).
109. Valdez R, Athens MA, Thompson GH, Bradshaw BS, Stern MP. Birthweight and adult health outcomes in a biethnic population in the USA. Diabetologia 37: 624-31 (1994).
110. Weitzman SA, Turk PW, Milkowski DH, Kozlowski K. Free radical adducts induce alterations in DNA cytosine methylation. Proc Natl Acad Sci USA 91: 1261-4 (1994).
111. Dalman C, Cullberg J. Neonatal hyperbilirubinaemia--a vulnerability factor for mental disorder? Acta Psychiatr Scand 100: 469-71 (1999).
112. De la Burde B, Choate MS, Jr. Does asymptomatic lead exposure in children have latent sequelae? J Pediatr 81: 1088-91 (1972).
113. Wu G, Bazer FW, Cudd TA, Meininger CJ, Spencer TE. Maternal nutrition and fetal development. J Nutr 134: 2169-72 (2004).
114. Gorell JM, Rybicki BA, Cole Johnson C, Peterson EL. Occupational metal exposures and the risk of Parkinson's disease. Neuroepidem 18: 303-8 (1999).
115. Stewart WF, Schwartz BS, Simon D, Kelsey K, Todd AC. ApoE genotype, past adult lead exposure, and neurobehavioral function. Environ Health Perspect 110: 501-5 (2002).
116. Castellani RJ, Lee HG, Perry G, Smith MA. Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau. Am J Alzheimers Dis Other Demen 21: 126-30 (2006).
117. Ono K, Hamaguchi T, Naiki H, Yamada M. Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. Biochim Biophys Acta 1762: 575-86 (2006).
118. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77: 1081-132 (1997).
119. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res 32: 4100-8 (2004).
120. Cecchi C, Fiorillo C, Sorbi S, et al. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med 33: 1372-9 (2002).
121. Wu J, Basha MR, Zawia NH. The environment, epigenetics and amyloidogenesis. J Mol Neurosci 34: 1-7 (2008).
122. Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 46: 1241-9 (2009).
123. Lahiri DK, Maloney B. The "LEARn" (Latent Early-life Associated Regulation) model integrates environmental risk factors and the developmental basis of Alzheimer's disease, and proposes remedial steps. Exp Gerontol 45: 291-6 (2010).
124. Lahiri DK, Zawia NH, Greig NH, Sambamurti K, Maloney B. Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model. Biogerontol: (2008).
125. Lee YA, Durandin A, Dedon PC, Geacintov NE, Shafirovich V. Oxidation of guanine in G, GG, and GGG sequence contexts by aromatic pyrenyl radical cations and carbonate radical anions: relationship between kinetics and distribution of alkali-labile lesions. J Phys Chem B 112: 1834-44 (2008).
126. Lahiri DK, Wavrant De-Vrieze F, Ge Y-W, Maloney B, Hardy J. Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset Alzheimer's disease. Neurobiol Aging 26: 1329-41 (2005).
127. Santos F, Hendrich B, Reik W, Dean W. Dynamic reprogramming of DNA methylation in the early mouse embryo. Dev Biol 241: 172-82 (2002).
128. Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr 135: 1382-6 (2005).
129. Poirier LA, Vlasova TI. The prospective role of abnormal methyl metabolism in cadmium toxicity. Environ Health Perspect 110 Suppl 5: 793-5 (2002).
130. Foster WG, McMahon A, Rice DC. Sperm chromatin structure is altered in cynomolgus monkeys with environmentally relevant blood lead levels. Toxicol Ind Health 12: 723-35 (1996).
131. Takiguchi M, Achanzar WE, Qu W, Li G, Waalkes MP. Effects of cadmium on DNA-(Cytosine-5) methyltransferase activity and DNA methylation status during cadmium-induced cellular transformation. Exp Cell Res 286: 355-65 (2003).
132. Pogribny I, Koturbash I, Tryndyak V, Hudson D, Stevenson SM, Sedelnikova O, et al. Fractionated low-dose radiation exposure leads to accumulation of DNA damage and profound alterations in DNA and histone methylation in the murine thymus. Mol Cancer Res 3: 553-61 (2005).
133. Becker FF, Holton P, Ruchirawat M, Lapeyre JN. Perturbation of maintenance and de novo DNA methylation in vitro by UVB (280-340 nm)-induced pyrimidine photodimers. Proc Natl Acad Sci USA 82: 6055-9 (1985).
134. Wilson VL, Jones PA. Inhibition of DNA methylation by chemical carcinogens in vitro. Cell 32: 239-46 (1983).
135. Turk PW, Weitzman SA. Free radical DNA adduct 8-OHdeoxyguanosine affects activity of Hpa II and Msp I restriction endonucleases. Free Radic Res 23: 255-8 (1995).
136. Kuchino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K, et al. Misreading of DNA templates containing 8- hydroxydeoxyguanosine at the modified base and at adjacent residues. Nature 327: 77-9 (1987).
137. Xiao W, Samson L. In vivo evidence for endogenous DNA alkylation damage as a source of spontaneous mutation in eukaryotic cells. Proc Natl Acad Sci U S A 90: 2117-21 (1993).
138. Bolin C, Stedeford T, Cardozo-Pelaez F. Single extraction protocol for the analysis of 8-hydroxy-2'-deoxyguanosine (oxo8dG) and the associated activity of 8-oxoguanine DNA glycosylase. J Neurosci Methods 136: 69-76 (2004).
139. Kriaucionis S, Heintz N. The nuclear DNA base 5- hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324: 929-30 (2009).
140. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5- hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930-5 (2009).
141. Iqbal K, Jin SG, Pfeifer GP, Szabo PE. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc Natl Acad Sci U S A 108: 3642-7 (2011).
142. Penn NW, Suwalski R, O'Riley C, Bojanowski K, Yura R. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem J 126: 781-90 (1972).
143. Szwagierczak A, Bultmann S, Schmidt CS, Spada F, Leonhardt H. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res 38: e181 (2010).
144. Muenzel M, Globisch D, Bruekl T, Wagner M, Welzmiller V, Michalakis S, et al. Quantification of the Sixth DNA Base Hydroxymethylcytosine in the Brain. Angew Chem Intl Ed 49: 5375-7 (2010).
145. Weitzman SA, Lee RM, Ouellette AJ. Alterations in c-abl gene methylation in cells transformed by phagocyte-generated oxidants. Biochem Biophys Res Commun 158: 24-30 (1989).
146. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature 397: 579-83 (1999).
147. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol 18: 6538-47 (1998).
148. Wolffe AP, Jones PL, Wade PA. DNA demethylation. Proc Natl Acad Sci USA 96: 5894-6 (1999).
149. Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 11: 607-20 (2010).
150. Miller CA, Sweatt JD. Covalent modification of DNA regulates memory formation. Neuron 53: 857-69 (2007).
151. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248: 1122-4 (1990).
152. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-41 (1999).
153. Lahiri DK, Maloney B. Environmental Effects on Sporadic Disorders can be Better Traced by a Kinetic "Longitudinal Epigenome/Environome-Wide Association Study" than by the Genome-Wide Association Study. IN PREPARATION: (2011).